/
CRL
$233.15+$6.36 (+2.80%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$10.9B
48M shares
52-week range
$144.26 – $236.62
96% from low
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NYSE
CS
Borrow rate
0.27%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-141.07
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.27B | $2.62B | $2.92B | $3.54B | $3.98B | $4.13B | $4.05B | $4.02B |
| Cost of revenue | $1.43B | $1.66B | $1.85B | $2.21B | $2.51B | $2.63B | $2.72B | $2.79B |
| Gross profit | $840.1M | $958.3M | $1.07B | $1.33B | $1.46B | $1.50B | $1.33B | $1.23B |
| Gross margin | 37.1% | 36.6% | 36.7% | 37.7% | 36.8% | 36.4% | 32.9% | 30.5% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $331.4M | $351.2M | $432.7M | $589.9M | $651.0M | $617.3M | $227.3M | $507.8M |
| EBITDA | $507.2M | $563.1M | $768.5M | $820.2M | $986.1M | $1.03B | $581.1M | $410.8M |
| Net income | $226.4M | $252.0M | $364.3M | $391.0M | $486.2M | $474.6M | $10.3M | −$144.3M |
| Net margin | 10.0% | 9.6% | 12.5% | 11.0% | 12.2% | 11.5% | 0.3% | -3.6% |
| EPS (diluted) | 4.62 | 5.07 | 7.20 | 7.60 | 9.48 | 9.22 | 0.20 | -2.91 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3.8B | $11.09 | $10.95–$11.20 | 10 |
| 2027 | $3.9B | $12.33 | $11.91–$12.60 | 10 |
| 2028 | $4.1B | $13.44 | $8.77–$16.48 | 5 |
| 2029 | $4.3B | $14.61 | $14.39–$14.98 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$97.62
Price
$233.15
Implied downside
-58%
Peer comparison
Charles River Laboratories International, Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
www.criver.com- Employees
- 19,700
- IPO / List date
- Jun 23, 2000
- HQ
- WILMINGTON, MA
Held by traders on TradeandTell
No one on the platform currently holds CRL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 10,200 | $2.0M |
| Bridgewater Associatesas of 2026-03-31 | 6,835 | $1.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CRL yet.
